Peter Werth

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

MedRhythms, Inc. is a digital therapeutics company based in Portland, ME. The company uses sensors, music, and software to develop evidence-based neurologic interventions to measure and improve walking. MedRhythms is dedicated to developing direct-stimulation digital therapeutics that provide direct stimulation to enable the mechanism of action in each relevant population. The company has an active pipeline of prescription digital therapeutics targeting rehabilitation and prevention in areas of neurologic injury and disease. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. MedRhythms is on a mission to help people living with neurologic injuries and diseases optimize their health and independence through next-generation therapeutics to improve brain health. MedRhythms was founded in 2013 by Brian Harris and Owen McCarth, with Brian Harris serving as the CEO since then.

MedRhythms, Inc. is a digital therapeutics company based in Portland, ME. The company uses sensors, music, and software to develop evidence-based neurologic interventions to measure and improve walking. MedRhythms is dedicated to developing direct-stimulation digital therapeutics that provide direct stimulation to enable the mechanism of action in each relevant population. The company has an active pipeline of prescription digital therapeutics targeting rehabilitation and prevention in areas of neurologic injury and disease. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. MedRhythms is on a mission to help people living with neurologic injuries and diseases optimize their health and independence through next-generation therapeutics to improve brain health. MedRhythms was founded in 2013 by Brian Harris and Owen McCarth, with Brian Harris serving as the CEO since then.

Chemwerth, Inc. develops and supplies pharmaceutical products. The company offers oral, injectable, veterinary, oncology, topical, investigational stage, and in development stage products. It also offers a range of services, including regulatory affairs and technical service department, as well as customs clearance and logistics support services. The company was founded by Peter J. Werth Jr in 1982 and is headquartered in Woodbridge, CT.

Likarda LLC is a cell therapy company that develops enabling technologies to improve the efficacy of cell therapies and provide sustainable reversal for chronic or fatal diseases. The private company's core technology is the core-shell spherification (CSS) technology, which coats cells and biologics with inert hydrogels to ensure they remain at their intended target location within the body and are shielded from potential degradation. Likarda is based in Cambridge, MA. This customizable platform is pivotal in maintaining cell viability and optimizing the delivery of biologics.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.

Chemwerth, Inc. develops and supplies pharmaceutical products. The company offers oral, injectable, veterinary, oncology, topical, investigational stage, and in development stage products. It also offers a range of services, including regulatory affairs and technical service department, as well as customs clearance and logistics support services. The company was founded by Peter J. Werth Jr in 1982 and is headquartered in Woodbridge, CT.

Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Likarda LLC is a cell therapy company that develops enabling technologies to improve the efficacy of cell therapies and provide sustainable reversal for chronic or fatal diseases. The private company's core technology is the core-shell spherification (CSS) technology, which coats cells and biologics with inert hydrogels to ensure they remain at their intended target location within the body and are shielded from potential degradation. Likarda is based in Cambridge, MA. This customizable platform is pivotal in maintaining cell viability and optimizing the delivery of biologics.

Likarda LLC is a cell therapy company that develops enabling technologies to improve the efficacy of cell therapies and provide sustainable reversal for chronic or fatal diseases. The private company's core technology is the core-shell spherification (CSS) technology, which coats cells and biologics with inert hydrogels to ensure they remain at their intended target location within the body and are shielded from potential degradation. Likarda is based in Cambridge, MA. This customizable platform is pivotal in maintaining cell viability and optimizing the delivery of biologics.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

MedRhythms, Inc. is a digital therapeutics company based in Portland, ME. The company uses sensors, music, and software to develop evidence-based neurologic interventions to measure and improve walking. MedRhythms is dedicated to developing direct-stimulation digital therapeutics that provide direct stimulation to enable the mechanism of action in each relevant population. The company has an active pipeline of prescription digital therapeutics targeting rehabilitation and prevention in areas of neurologic injury and disease. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. MedRhythms is on a mission to help people living with neurologic injuries and diseases optimize their health and independence through next-generation therapeutics to improve brain health. MedRhythms was founded in 2013 by Brian Harris and Owen McCarth, with Brian Harris serving as the CEO since then.

Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.

Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.

Chemwerth, Inc. develops and supplies pharmaceutical products. The company offers oral, injectable, veterinary, oncology, topical, investigational stage, and in development stage products. It also offers a range of services, including regulatory affairs and technical service department, as well as customs clearance and logistics support services. The company was founded by Peter J. Werth Jr in 1982 and is headquartered in Woodbridge, CT.

Chemwerth, Inc. develops and supplies pharmaceutical products. The company offers oral, injectable, veterinary, oncology, topical, investigational stage, and in development stage products. It also offers a range of services, including regulatory affairs and technical service department, as well as customs clearance and logistics support services. The company was founded by Peter J. Werth Jr in 1982 and is headquartered in Woodbridge, CT.

MedRhythms, Inc. is a digital therapeutics company based in Portland, ME. The company uses sensors, music, and software to develop evidence-based neurologic interventions to measure and improve walking. MedRhythms is dedicated to developing direct-stimulation digital therapeutics that provide direct stimulation to enable the mechanism of action in each relevant population. The company has an active pipeline of prescription digital therapeutics targeting rehabilitation and prevention in areas of neurologic injury and disease. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. MedRhythms is on a mission to help people living with neurologic injuries and diseases optimize their health and independence through next-generation therapeutics to improve brain health. MedRhythms was founded in 2013 by Brian Harris and Owen McCarth, with Brian Harris serving as the CEO since then.

Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.

Chemwerth, Inc. develops and supplies pharmaceutical products. The company offers oral, injectable, veterinary, oncology, topical, investigational stage, and in development stage products. It also offers a range of services, including regulatory affairs and technical service department, as well as customs clearance and logistics support services. The company was founded by Peter J. Werth Jr in 1982 and is headquartered in Woodbridge, CT.

Chemwerth, Inc. develops and supplies pharmaceutical products. The company offers oral, injectable, veterinary, oncology, topical, investigational stage, and in development stage products. It also offers a range of services, including regulatory affairs and technical service department, as well as customs clearance and logistics support services. The company was founded by Peter J. Werth Jr in 1982 and is headquartered in Woodbridge, CT.

Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.

MedRhythms, Inc. is a digital therapeutics company based in Portland, ME. The company uses sensors, music, and software to develop evidence-based neurologic interventions to measure and improve walking. MedRhythms is dedicated to developing direct-stimulation digital therapeutics that provide direct stimulation to enable the mechanism of action in each relevant population. The company has an active pipeline of prescription digital therapeutics targeting rehabilitation and prevention in areas of neurologic injury and disease. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. MedRhythms is on a mission to help people living with neurologic injuries and diseases optimize their health and independence through next-generation therapeutics to improve brain health. MedRhythms was founded in 2013 by Brian Harris and Owen McCarth, with Brian Harris serving as the CEO since then.

VM Pharma LLC develops and identifies allosteric kinase inhibitors. The firm specializes in the treatment of pain, cancer, and other human diseases. The company is headquartered in Fremont, CA.